Intravenous iron therapy for treatment of anaemia: Time for cautious optimism, not wide adoption

BMJ (Online)

Volumn 347, Issue 7923, 2013, Pages

  McIntyre, L A ^a   Tinmouth, A ^a   Fergusson, D ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; ERYTHROPOIETIN; FERRITIN; HEMOGLOBIN; IRON;

ANEMIA; BLOOD TRANSFUSION REACTION; BLOODSTREAM INFECTION; DRUG ABSORPTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; EDITORIAL; ERYTHROCYTE TRANSFUSION; FERRITIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; INFECTION RISK; IRON ABSORPTION; IRON DEFICIENCY ANEMIA; IRON THERAPY; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK REDUCTION; TREATMENT OUTCOME;

BLOOD TRANSFUSION; HUMANS; IRON;

EID: 84883801894     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.f5378     Document Type: Editorial

References (14)

1. Goodnough LT. Iron deficiency syndromes and iron-restricted erythropoiesis (CME). Transfusion 2012;52:1584-92.
2. Auerbach M, Ballard H. Clinical use of intravenous iron: administration, efficacy, and safety. Hematology Am Soc Hematol Educ Program 2010;2010:338-47.
3. Auerbach M, Coyne D, Ballard H. Intravenous iron: from anathema to standard of care. Am J Hematol 2008;83:580-8. (Pubitemid 351874877)
4. Litton E, Xiao J, Ho KM. Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials. BMJ 2013;347:f4822.
5. McIntyre L, Tinmouth AT, Fergusson DA. Blood component transfusion in critically ill patients. Curr Opin Crit Care 2013;19:326-33.
6. Callum JL, Lin Y, Pinkerton PH, Karkouti JM, Prendergast M. Risk charts reference for physicians. Bloody easy 3: blood transfusions, blood alternatives and transfusion reactions,a guide to transfusion medicine . 3rd ed. ORBICoN, 2011:34-73.
7. Marik PE, Corwin HL. Efficacy of red blood cell transfusion in the critically ill: a systematic review of the literature. Crit Care Med 2008;36:2667-74.
8. Laupacis A, Fergusson D. Drugs to minimize perioperative blood loss in cardiac surgery: meta-analyses using perioperative blood transfusion as the outcome. The International Study of Peri-operative Transfusion (ISPOT) Investigators. Anesthesia Analgesia 1997;85:1258-67. (Pubitemid 28130521)
9. Corwin HL, Gettinger A, Rodriguez RM, Pearl RG, Gubler KD, Enny C, et al. Efficacy of recombinant human erythropoietin in the critically ill patient: a randomized, double-blind, placebo-controlled trial. Crit Care Med 1999;27:2346-50.
10. Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Shapiro MJ, et al. Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. JAMA 2002;288:2827-35. (Pubitemid 35425068)
11. Corwin HL, Gettinger A, Fabian TC, May A, Pearl RG, Heard S, et al. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med 2007;357:965-76. (Pubitemid 47367076)
12. Fergusson DA, Hebert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008;358:2319-31. (Pubitemid 351749156)
13. Albaramki J, Hodson EM, Craig JC, Webster AC. Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database Syst Rev 2012;(1):CD007857.
14. Guyatt GH, Naylor CD, Juniper E, Heyland DK, Jaeschke R, Cook DJ. Users' guide to the medical literature XII. How to use articles about health-related quality of life. JAMA 1997;277:1232-7. (Pubitemid 27172748)